Humacyte (NASDAQ:HUMA) Stock Price Expected to Rise, Benchmark Analyst Says

Humacyte (NASDAQ:HUMA) had its price objective boosted by Benchmark from $15.00 to $17.00 in a report published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target (up previously from $12.00) on shares of Humacyte in a report on Friday. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research note on Friday. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Humacyte has a consensus rating of “Buy” and an average price target of $13.71.

Humacyte Trading Up 0.2 %

Shares of NASDAQ:HUMA opened at $4.65 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The company’s 50-day moving average price is $4.81 and its 200 day moving average price is $5.81. The company has a market cap of $585.24 million, a PE ratio of -3.47 and a beta of 1.38. Humacyte has a fifty-two week low of $2.48 and a fifty-two week high of $9.97.

Insider Activity

In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. This represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,500,000 shares of company stock worth $6,606,799 over the last 90 days. 11.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently modified their holdings of HUMA. nVerses Capital LLC purchased a new stake in shares of Humacyte during the second quarter valued at $28,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the 3rd quarter worth about $75,000. Principal Financial Group Inc. acquired a new stake in Humacyte during the 2nd quarter worth about $83,000. FORA Capital LLC purchased a new stake in Humacyte during the third quarter valued at about $96,000. Finally, Profund Advisors LLC acquired a new position in shares of Humacyte in the second quarter worth about $97,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.